BOHEMIA, N.Y., Jan. 26, 2005 (PRIMEZONE) -- OmniCorder Technologies, Inc. (OTCBB:OMCT), a leading developer of functional medical imaging systems, today announced the launch of a new corporate website. After several months of design, development and content review, OmniCorder is proud to direct investors, clinicians, patients, customers and the general public to www.omnicorder.com. The website has a new look and feel and focuses on the BioScanIR(R) System, the company's functional medical imaging modality.
"The new website better reflects who we are as a company and is a great resource for anyone wanting information about OmniCorder and the BioScanIR(R) System. As an integral part of our marketing and communications programs, we will continue to update the site with new clinical data, product information and corporate news," stated Michael A. Davis, M.D., Chairman of the Executive Committee of OmniCorder's Board of Directors.
The BioScanIR(R) System:
The Company's BioScanIR System is a functional medical imaging modality that provides a fast, non-invasive, radiation-free method for detecting and managing a wide variety of diseases that affect blood perfusion --such as cancer and vascular disease -- by detecting minute changes in temperature based on the pattern of infrared photon emissions over time. The detector technology used in the system, known as a Quantum Well Infrared Photodetector (QWIP), was originally developed for the Department of Defense by NASA's Jet Propulsion Laboratory. The Company owns an exclusive, worldwide license to use the technology for biomedical applications.
OmniCorder has successfully used the BioScanIR System in a number of key medical markets, including: Breast Cancer Detection, Cancer Therapy Monitoring, Drug Discovery, Neurosurgery and Reconstructive Surgery. The System has the capacity to cost-effectively improve disease detection, enhance clinical decision making and improve therapy management in a vast number of medical applications.
About OmniCorder Technologies, Inc.:
OmniCorder Technologies Inc., headquartered in Bohemia, New York, is a leading developer of functional medical imaging applications using advanced infrared focal plane arrays. OmniCorder's imaging technology has utility for clinicians and researchers in drug discovery, disease detection and disease management applications.
OmniCorder's mission is to improve the quality and cost-effectiveness of healthcare services and research through identifying, acquiring and adapting high-resolution infrared technology for biomedical applications.
This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe", "estimate", "project", "expect" or similar expressions. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance of the Company's products and services in the marketplace, the ability of the Company to develop effective new products and receive governmental approvals of such products, competitive factors, dependence upon third-party vendors, and other risks detailed in the Company's periodic report filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release.